ArticleRegenerative therapy2026
Prednisolone attenuates the immunomodulatory capacity and reshapes the functional phenotype of canine adipose-derived mesenchymal stromal cells.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mesenchymal stromal cells (MSCs) are a promising therapeutic option for refractory canine chronic inflammatory enteropathy (CIE), primarily because of their immunomodulatory properties. However, MSC function may be influenced by concomitant medications, including prednisolone. Therefore, we investigated the effects of prednisolone on canine adipose-derived MSCs (cADSCs), with particular focus on immunomodulatory capacity and migratory behavior. Methods: Effects on the biological and functional properties of cADSCs were evaluated following treatment with prednisolone ranging from 0.01 to 100 μM. Morphology, senescence, apoptosis, proliferation, cell-cycle distribution, mitochondrial activity, migration, and invasion were assessed. Immunomodulatory function was assessed by co-culture assays using DH82 macrophages and canine peripheral blood mononuclear cells (PBMCs), including analyses of macrophage polarization, regulatory T-cell induction, T-cell subset composition, activation, and proliferation. RNA sequencing was performed to characterize transcriptomic changes in cADSCs treated with or without prednisolone and cultured with or without activated PBMCs. Results: Prednisolone did not induce apparent morphological changes, senescence, or apoptosis in cADSCs, but altered proliferation, mitochondrial activity, and migratory behavior and attenuated key immunomodulatory functions. RNA sequencing revealed that prednisolone suppressed inflammatory signaling in cADSCs under basal conditions, whereas these cells retained robust inflammatory transcriptional responsiveness to signals derived from activated PBMC. Conclusions: Prednisolone reshapes cADSC function in a context-dependent manner, reducing immunomodulatory capacity without substantially impairing viability. These findings suggest that glucocorticoid exposure and inflammatory activation interact to modulate cADSC function and should be considered when optimizing MSC-based therapy for canine CIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.